The leading biotechnology company developing alpha particle linked antibodies to treat cancer


Iomab-B will begin a pivotal trial for preparing bone marrow of patients with certain blood cancers before they receive a hematopoietic stem cell transplant or HSCT. View Key Opinion Leader Panel Discussion


Actimab-A Is in a Phase I/II Clinical Trial.  View Key Opinion Leader Panel Discussion


Technology platform couples monoclonal antibodies with extremely potent but comparatively safe radioactive isotopes, in particular the alpha-emitter Actinium 225